Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01689324
Other study ID # Td540
Secondary ID U1111-1124-7671
Status Completed
Phase Phase 1/Phase 2
First received September 17, 2012
Last updated February 19, 2014
Start date September 2012
Est. completion date May 2013

Study information

Verified date February 2014
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

This study is designed to assess the immunogenicity and safety of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (ADACEL®, Tdap vaccine) as a booster dose in adolescents in Japan.

Primary Objective:

- To assess the immunogenicity of Tdap (SP306) when administered as a single dose in Japanese adolescents

Secondary Objective:

- To assess the safety of Tdap vaccine when administered as a single dose in Japanese adolescents.


Description:

All participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0 and undergo immunogenicity assessment from blood samples provided prior to, and 28 days post-vaccination. Tolerability and safety will be monitored up to 28 days post-vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date May 2013
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 11 Years to 12 Years
Eligibility Inclusion Criteria:

- Aged 11 or 12 years on the day of inclusion

- Informed consent form and assent form signed and dated by the parent(s) / legal representative and the subject respectively

- Completed childhood vaccination against diphtheria, pertussis and tetanus (i.e, received 4 doses of Japanese-produced tetanus toxoid, diphtheria toxoid and acellular pertussis vaccine absorbed [DTaP vaccine]), confirmed by checking immunization records and have not yet undergone additional adsorbed Diphtheria and Tetanus toxoid (DT) vaccination

- Able to attend all scheduled visits and to comply with all trial procedures

- For female subjects, either pre-menarchal, or post-menarchal with a negative urine pregnancy test.

Exclusion Criteria:

- Any conditions or diseases which, in the opinion of the investigator

- would pose a health risk to the subject

- or might interfere with the ability to participate fully in the study

- or might interfere with evaluation of the vaccine

- or would otherwise make participation inappropriate according to the investigator's clinical judgment

- History of diphtheria, tetanus, pertussis, confirmed either clinically, serologically, or microbiologically

- Known systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to a vaccine containing the same substances of the study vaccine

- Vaccination in the last 5 years against tetanus, diphtheria, and/or pertussis

- Known or suspected congenital immunodeficiency, or current / previous acquired immunodeficiency, or current / previous receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, or current / previous (within the last 6 months) systemic corticosteroid therapy

- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial inclusion

- Planned participation in another clinical trial during the present trial period

- Receipt of blood or blood-derived products in the past 3 months, that might interfere with assessment of the immune response

- Receipt of any vaccine within the 4 weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least 2 weeks before the study vaccine

- Planned receipt of any vaccine during the trial period

- Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection

- At high risk for diphtheria, tetanus or pertussis infection during the trial

- Known pregnancy, or a positive urine pregnancy test

- Currently breastfeeding a child

- Known thrombocytopenia, contraindicating intramuscular (IM) vaccination, or a history of thrombocytopenia

- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination

- History of acute disseminated encephalomyelitis, encephalopathy, Guillain-Barré Syndrome (GBS), or autoimmune disease

- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily

- Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

- Identified as an employee of an Investigator, a study center, a study-affiliated vendor, or the Sponsor, with direct or indirect involvement in the proposed study or other studies under the direction of that Investigator or study center; or identified as a spouse or child (whether natural or adopted) of such an employee.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis
0.5 mL, Intramuscular

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination With ADACEL® Seroprotection was defined as the percentage of participants with antibody concentration of =0.1 IU/mL. Day 0 pre-vaccination No
Other Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Pre-vaccination and Post-vaccination With ADACEL® Seroprotection was defined as the percentage of participants with antibody concentration of =0.01 IU/mL. Day 0 (pre-vaccination) and day 28 post-vaccination No
Other Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Pre-vaccination and Post-vaccination With ADACEL® Seroprotection was defined as the percentage of participants with antibody concentration of =1.0 IU/mL. Day 0 (pre-vaccination) and day 28 post-vaccination No
Other Geometric Mean Concentrations With Respect to Diphtheria and Tetanus Antibodies Pre- and Post-vaccination With ADACEL® Day 0 (pre-vaccination) and Day 28 post-vaccination No
Other Geometric Mean Concentrations With Respect to Pertussis Antibodies Pre- and Post-vaccination With ADACEL® Day 0 (pre-vaccination) and Day 28 post-vaccination No
Other Percentage of Participants With Booster Response to Pertussis Antigens, Pertactin and Fimbriae Following Vaccination With ADACEL® Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels = 4x LLOQ; or Pre-vaccination antibody concentrations = LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination = 4), or Pre-vaccination antibody concentrations = 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination = 2) Day 28 post-vaccination No
Other Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With ADACEL® Solicited injection-site reactions: Pain, Redness, and Swelling. Grade 3: Pain, Significant, prevents daily activity; Redness and Swelling, >100 mm.
Solicited systemic reactions: Fever (Temperature); Headache, Malaise, and Myalgia. Grade 3: Fever, = 39°C; Headache, Malaise and Myalgia, Significant, prevents daily activity.
Day 0 up to Day 7 post-vaccination No
Primary Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® Seroprotection was defined as the percentage of participants with antibody concentration of =0.1 IU/mL, post-vaccination. Day 28 post-vaccination No
Primary Percentage of Participants With Booster Response to Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® Diphtheria booster response was defined as a = 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration = 2.56 IU/mL; or a = 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.56 IU/mL.
Tetanus booster response was defined as a = 4-fold rise in pre- to post- vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration = 2.7 IU/mL; or a = 2-fold rise in a subject with a pre-vaccination antitoxin concentration > 2.7 IU/mL.
Day 28 post-vaccination No
Primary Percentage of Participants With Booster Response to Pertussis Antigens, Pertussis Toxoid and Filamentous Hemagglutinin Following Vaccination With ADACEL® Booster responses were defined as: Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) and a post-vaccination levels = 4x LLOQ; or Pre-vaccination antibody concentrations = LLOQ but < 4x LLOQ, and a 4-fold rise (i.e., post-/pre-vaccination = 4), or Pre-vaccination antibody concentrations = 4x LLOQ and a 2-fold rise (i.e., post-/pre-vaccination = 2) Day 28 post-vaccination No
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3
Active, not recruiting NCT05091619 - A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Phase 3

External Links